State drug pricing policies Drug companies and PBMs should prepare for continued activity [REPORT]

US states are pulling various levers to address rising drug prices. An analysis of public databases and interviews with experts show us the areas under focus, the stakeholders that could be affected, and what strategies they should consider.

Drug pricing proposals at the federal level have stalled, but states have acted to address rising drug prices and are likely to return to this agenda as they find budgets under strain following COVID-19. The Deloitte Center for Health Solutions analyzed publicly available databases and interviewed individuals who have worked on formulating and implementing policies at the state level to find out what legislative and policy proposals have been enacted or are being considered. We discovered there was much activity around drug pricing that could potentially affect pharmacy benefit managers (PBMs), health plans, and drug companies, though the impact on overall spending to date is less clear.

To download report CLICK HERE.